Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 676 - 700 of 15218 in total

Sparsentan

Sparsentan is a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin II (Ang II) type 1 receptor (AT1R) with a similar affinity for both (9.3 nM for ETAR and 0.8 nM for AT1R).[A257330,L45300] Sparsentan is first in its class and orally active, and was created by...
Approved
Investigational
Matched Description: … [A257330,L45300] Sparsentan is first in its class and orally active, and was created by merging the structural ... Sparsentan is a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin ... [L45315] The use of sparsentan may cause hepatotoxicity and embryo-fetal toxicity.[L45300] …

Parthenolide

Parthenolide has been used in trials studying the diagnostic of Allergic Contact Dermatitis.
Approved
Investigational

Methoxyphenamine

Approved

Fluticasone

Fluticasone is a synthetic glucocorticoid available as 2 esters, DB08906 and DB00588[F4355,F4358,F4361,F4364][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358,F4361,F4364][FDA Label]. DB00588 was first approved in 1990 and DB08906 was approved in 2007 .
Approved
Experimental
Matched Description: … [DB00588] was first approved in 1990[L5962] and [DB08906] was approved in 2007[L5965]. ... Fluticasone is a synthetic glucocorticoid available as 2 esters, [DB08906] and [DB00588][F4355,F4358, ... These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory …
Matched Categories: … formoterol and fluticasone ... salmeterol and fluticasone …

Betaxolol

A cardioselective beta-1-adrenergic antagonist with no partial agonist activity.
Approved
Investigational
Matched Categories: … Antiglaucoma Preparations and Miotics …

Milrinone

Heart failure is a multifactorial condition that affects roughly 1-2% of the adult population. Often the result of long-term myocardial ischemia, cardiomyopathy, or other cardiac insults, heart failure results from an inability of the heart to perfuse peripheral tissues with sufficient oxygen and metabolites, resulting in complex systemic pathologies. Heart...
Approved
Matched Description: … and peripheral vasodilation in acute decongested heart failure. ... failure results from an inability of the heart to perfuse peripheral tissues with sufficient oxygen and ... cyclic adenosine monophosphate (cAMP) production, which affects the heart's contractile function and …

Butorphanol

A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.
Approved
Illicit
Vet approved

Eplerenone

Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of...
Approved
Matched Description: … antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and ... The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the ... mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …

Nalbuphine

A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States.
Approved
Matched Description: … It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid …

Almotriptan

Almotriptan is a triptan drug for the treatment of migraine headaches. Almotriptan is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and stopping the release of certain natural substances that...
Approved
Investigational
Matched Description: … works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and ... stopping the release of certain natural substances that cause pain, nausea, and other symptoms of migraine …
Matched Categories: … Serotonin-1b and Serotonin-1d Receptor Agonist …

Dalfampridine

Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Approved

Deferasirox

Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Approved
Investigational
Matched Iupac: … 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid …
Matched Description: … Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload …

Alfuzosin

Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases...
Approved
Investigational
Matched Description: … Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads ... to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. ... The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to …
Matched Categories: … alfuzosin and finasteride ... Genito Urinary System and Sex Hormones …

Sodium aurothiomalate

Sodium aurothiomalate is a gold compound that is used for its immunosuppressive anti-rheumatic effects. Gold Sodium Thiomalate is supplied as a solution for intramuscular injection containing 50 mg of Gold Sodium Thiomalate per mL. It is most effective in active progressive rheumatoid arthritis and of little or no value in...
Approved
Investigational
Matched Description: … It is most effective in active progressive rheumatoid arthritis and of little or no value in the presence …
Matched Categories: … Antiinflammatory and Antirheumatic Products …

Bepotastine

Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name Talion. It is available...
Approved
Matched Iupac: … 4-{4-[(4-chlorophenyl)(pyridin-2-yl)methoxy]piperidin-1-yl}butanoic acid …
Matched Description: … in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand ... It is available in oral and opthalmic dosage forms in Japan. ... The opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve. …

Encainide

All drug products containing encainide hydrochloride. Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack. The manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991.
Approved
Investigational
Withdrawn

Omadacycline

Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent...
Approved
Investigational
Matched Description: … diseases and blood-borne infections in both the hospital and community settings. ... Skin Structures and Soft Tissue Infections. ... studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and …

Lomitapide

Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R).
Approved
Investigational

Pretomanid

Persistent forms of tuberculosis (TB) have proven to be a major cause of global morbidity and mortality and a cause for significant concern. Research in recent years has been geared toward the development of novel therapies that target persistent forms of this disease, which have shown resistance to standard therapy...
Approved
Matched Description: … and a cause for significant concern. ... Persistent forms of tuberculosis (TB) have proven to be a major cause of global morbidity and mortality ... It was the first TB drug developed by a nonprofit organization, known as TB Alliance, and was granted …

Tapentadol

Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011....
Approved

Tropisetron

Tropisetron is an indole derivative with antiemetic activity. As a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. Tropisetron appears to be well tolerated with the most frequently reported adverse effect being headache. Extrapyramidal...
Approved
Investigational
Matched Description: … radiotherapy-induced nausea and vomiting. ... competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and …
Matched Categories: … Alimentary Tract and Metabolism ... Antiemetics and Antinauseants …

Medroxyprogesterone acetate

Medroxyprogesterone acetate (MPA) is a progesterone derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also...
Approved
Investigational
Matched Description: … in palliative care for endometrial and renal carcinoma. ... vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also used ... endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and …
Matched Categories: … Hormones and Related Agents ... Progesterone and Derivatives ... medroxyprogesterone and estrogen ... medroxyprogesterone and estrogen ... medroxyprogesterone and estradiol …

Nicergoline

An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. It has been suggested to ameliorate cognitive deficits in cerebrovascular disease.
Approved
Investigational
Matched Description: … An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. …
Matched Categories: … Ergot Alkaloids and Derivatives …

Sarecycline

Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe facial acne vulgaris [A39993,...
Approved
Investigational
Matched Description: … the face but on the back and chest as well [L4814]. ... of hair follicles and their accompanying sebaceous glands [L4814]. ... to severe facial acne vulgaris [A39993, A39994] the US Food and Drug Administration approved Barcelona …

Nilotinib

Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant...
Approved
Investigational
Matched Description: … A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Displaying drugs 676 - 700 of 15218 in total